Ergoloid Tablets and Fiorinal w/Codeine

• Generic Name: ergoloid mesylates
• Dosage Forms: tablet
• Other Brand Names: Hydergine, Hydergine LC

Ergoloid mesylates is used to improve cognitive (mental) and self-care functioning in people with symptoms of dementia related to aging or conditions such as Alzheimer's disease.

Ergoloid mesylates is not a cure for dementia or for any underlying disease that may lead to decreased mental capacity.

Ergoloid mesylates will not treat dementia that is related to mental illness, mood disorders, or neurologic disease.

Ergoloid mesylates may also be used for purposes not listed in this medication guide.

• Generic Name: aspirin / butalbital / caffeine / codeine
• Dosage Forms: n.a.
• Other Brand Names: Ascomp with Codeine, Fiorinal with Codeine, Fiortal with Codeine, Ascomp-Codeine, Fiorinal/Codeine #3

Butalbital, aspirin, caffeine, and codeine combination is used to relieve symptoms of tension (or muscle contraction) headaches. Extended and repeated use of this product is not recommended.

Butalbital belongs to the group of medicines called barbiturates. Barbiturates act in the central nervous system (CNS) to produce their effects.

Aspirin is used to relieve pain and reduce fever in patients. It belongs to the group of medicines known as salicylates and acts on the immune system to reduce inflammation. It is also known as an anti-inflammatory analgesic.

Caffeine is a CNS stimulant that is used with pain relievers to increase their effect. It has also been used for migraine headaches. Codeine belongs to the group of medicine called narcotic analgesics (pain medicines). It acts on the central nervous system (CNS) to relieve pain.

When butalbital or codeine is used for a long time or in large doses, it may become habit-forming, causing mental or physical dependence. Physical dependence may lead to withdrawal side effects when you suddenly stop taking the medicine. In patients who get headaches, the first symptom of withdrawal may be new (rebound) headaches.

This medicine is available only under a restricted distribution program called the Opioid Analgesic REMS (Risk Evaluation and Mitigation Strategy) program.